Search results for "Neoplastic"

showing 10 items of 2901 documents

Oral microbiome in Proliferative Verrucous Leukoplakia exhibits loss of diversity and enrichment of pathogens.

2021

Abstract Objectives Oral microbiome plays an important role in oral diseases. Among them, proliferative verrucous leucoplakia (PVL) is an uncommon form of progressive multifocal leukoplakia with a worryingly rate of malignant transformation. Here, we aimed to characterize the oral microbiome of PVL patients and compare it with those of healthy controls. Material and methods Oral biopsies from ten PVL patients and five healthy individuals were obtained and used to compare their microbial communities. The sequence of the V3-V4 region of 16S rRNA gene was used as the taxonomic basis to estimate and analyze the composition and diversity of bacterial populations present in the samples. Results O…

Cancer ResearchBiopsymedicine.disease_causeCampylobacter jejuniRNA Ribosomal 16SmedicineProliferative verrucous leukoplakiaHumansEubacteriumLeukoplakiaMouthbiologyCampylobacterMicrobiotabiochemical phenomena metabolism and nutritionrespiratory systembacterial infections and mycosesbiology.organism_classificationmedicine.disease16S ribosomal RNAstomatognathic diseasesCell Transformation NeoplasticOncologyImmunologyOral MicrobiomeOral SurgeryLeukoplakia OralDysbiosisOral oncology
researchProduct

Expression of the IAPs in multidrug resistant tumor cells

2003

We have investigated the expression of the IAPs (inhibitory of apoptosis proteins) in the human HL-60 leukemia and in its multidrug resistant, P-glycoprotein (P-gp) over-expressing variant, HL-60R. HL-60R exhibits resistance to apoptosis induced from P-gp substrate drugs and also from other triggers (cisplatin, TNF-alpha, Fas ligation, TRAIL, IFN-gamma and serum starvation) not related to the multidrug transporter. Except for c-IAP-1 mRNA, HL-60R significantly over-expressed both the mRNAs and the proteins of all the IAPs studied, i.e. c-IAP-1, c-IAP-2, XIAP, NAIP and survivin. Determination of the DNA-binding capacity of NF-kappaB (p50 or p65 subunits) indicated that, while HL-60 cells sho…

Cancer ResearchBlotting WesternCellApoptosisHL-60 CellsBiologyInhibitor of Apoptosis Proteinsmultidrug resistanceSurvivinmedicineHumansRNA MessengerCisplatinOncogeneReverse Transcriptase Polymerase Chain ReactionNF-kappa BProteinsGeneral MedicineIAPCell cycleapoptosiMolecular biologyDrug Resistance MultipleXIAPGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyDrug Resistance NeoplasmApoptosisCancer researchNAIPmedicine.drugOncology Reports
researchProduct

Glucose metabolism of malignant cells is not regulated by transketolase-like (TKTL)-1.

2010

An isoenzyme of transketolase, transketolase-like (TKTL)-1, has been hypothesized to play a pivotal role in the pathophysiology of malignant tumors. Available data are based on the detection of the putative TKTL-1 protein with one particular mouse monoclonal anti-TKTL-1 antibody, clone JFC12T10. In this study it was demonstrated that a) JFC12T10 detects multiple unspecific bands in Western blots, b) a 75-kDa band hitherto referred to as TKTL-1 corresponds to a nuclear protein and c) immunohistochemical detection of TKTL-1 in benign leiomyomas yields an expression pattern identical to that found in a variety of malignant tumors. In RT-PCR assays, using three different primer pairs for transk…

Cancer ResearchBlotting WesternClone (cell biology)TransketolaseBiologyIsozymeGene Expression Regulation EnzymologicMiceCell Line TumorNeoplasmsAnimalsHumansNuclear proteinTumor hypoxiaOncogeneLeiomyomaAntibodies MonoclonalCell cycleGene Expression Regulation NeoplasticGlucoseOncologyBiochemistryMonoclonalUterine NeoplasmsCancer researchFemaleTransketolaseHeLa CellsInternational journal of oncology
researchProduct

The effects of the macrocyclic lactone bryostatin-1 on leukemic cells in vitro.

1992

The macrocyclic lactone bryostatin-1 was found to exert in vitro antineoplastic activity against several leukemic cell lines, including human K562 erythroleukemia, HL60 promyelocytic leukemia, REH and MOLT-4 lymphoblastic leukemias, CCRFCEM lymphoma, KG-1 myeloid leukemia, and murine P388 lymphocytic leukemia. No statistically significant difference in sensitivity to bryostatin-1 was found between adriamycin-resistant P388 and K526 subclones and their sensitive counterparts. Freshly explanted clonogenic leukemic cells showed a variable sensitivity to bryostatin-1 in 10/12 tested samples. The IC50 of clonogenic leukemic cells was 4 × 10–3 M bryostatin-1, and that of normal marrow CFU-GM was…

Cancer ResearchBryostatin 1LymphomaHL60Antineoplastic AgentsAntileukemic agent030218 nuclear medicine & medical imaging03 medical and health scienceschemistry.chemical_compoundLactones0302 clinical medicinehemic and lymphatic diseasesmedicineTumor Cells CulturedHumansClonogenic assayTumor Stem Cell AssayLeukemiaChemistryMyeloid leukemiaGeneral Medicinemedicine.diseaseBryostatinsHaematopoiesisLeukemiaOncology030220 oncology & carcinogenesisCancer researchMacrolidesDrug Screening Assays AntitumorK562 cellsTumori
researchProduct

Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.

2018

Primary liver cancer (PLC) ranks among the most lethal solid cancers worldwide due to lack of effective biomarkers for early detection and limited treatment options in advanced stages. Development of primary culture models that closely recapitulate phenotypic and molecular diversities of PLC is urgently needed to improve the patient outcome. Long-term cultures of 7 primary liver cancer cell lines of hepatocellular and cholangiocellular origin were established using defined culture conditions. Morphological and histological characteristics of obtained cell lines and xenograft tumors were analyzed and compared to original tumors. Time course analyses of transcriptomic and genomic changes were…

Cancer ResearchCarcinogenesisDNA Mutational AnalysisPrimary Cell CultureAntineoplastic AgentsDiseaseBiologymedicine.disease_causeTranscriptome03 medical and health sciencesMice0302 clinical medicineCell Line TumormedicineBiomarkers TumorAnimalsHumansPrecision MedicineDrug discoveryGene Expression ProfilingLiver NeoplasmsHigh-Throughput Nucleotide SequencingGenomicsPrecision medicinemedicine.diseasePhenotypeXenograft Model Antitumor AssaysOncologyCell culture030220 oncology & carcinogenesisMutationCancer researchKRASLiver cancerInternational journal of cancer
researchProduct

The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism

2012

In a previous work of ours dehydroxymethyl-epoxyquinomicin (DHMEQ), an inhibitor of NF-κB, was shown to induce apoptosis through Reactive Oxygen Species (ROS) production in hepatoma cells. The present study demonstrated that DHMEQ cooperates with Celecoxib (CLX) to decrease NF-κB DNA binding and to inhibit cell growth and proliferation more effectively than treatment with these single agents alone in the hepatoma cell lines HA22T/VGH and Huh-6. ROS production induced by the DHMEQ-CLX combination in turn generated the expression of genes involved in endoplasmic reticulum (ER) stress and silencing TRB3 mRNA significantly decreased DHMEQ-CLX-induced cell growth inhibition. Moreover, the DHMEQ-…

Cancer ResearchCarcinoma HepatocellularAntineoplastic AgentsApoptosisCell Cycle ProteinsProtein Serine-Threonine KinasesBiologyDHMEQ Celecoxib NF-jB CD95/CD95L Liver cancer cellsCell Line TumorSurvivinHumansGene silencingfas ReceptorProtein kinase BCell ProliferationSulfonamidesGene knockdownCyclooxygenase 2 InhibitorsCyclohexanonesCell growthEndoplasmic reticulumLiver NeoplasmsNF-kappa BDrug SynergismEndoplasmic Reticulum StressMolecular biologyAcetylcysteineRepressor ProteinsOncologyCelecoxibCell cultureApoptosisBenzamidesCancer researchPyrazolesPoly(ADP-ribose) PolymerasesReactive Oxygen SpeciesCancer Letters
researchProduct

Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction

2006

Abstract Background Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide and a major cause of cancer-related mortality. HCC is highly resistant to currently available chemotherapeutic drugs. Defects in apoptosis signaling contribute to this resistance. Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic member of the Bcl-2 protein family which interferes with mitochondrial activation. In a previous study we have shown that Mcl-1 is highly expressed in tissues of human HCC. In this study, we manipulated expression of the Mcl-1 protein in HCC cells by RNA interference and analyzed its impact on apoptosis sensitivity of HCC cells in vitro. Methods RNA interference was per…

Cancer ResearchCarcinoma HepatocellularMyeloidCellAntineoplastic AgentsApoptosisBiologylcsh:RC254-282RNA interferenceCell Line Tumorhemic and lymphatic diseasesGeneticsmedicineHumansneoplasmsLiver Neoplasmslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseasesIn vitroNeoplasm ProteinsGene Expression Regulation NeoplasticLeukemiamedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2OncologyApoptosisHepatocellular carcinomaCancer researchMyeloid Cell Leukemia Sequence 1 ProteinRNA InterferenceStem cellResearch ArticleBMC Cancer
researchProduct

Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour …

2016

Abstract Objective To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL). Material and methods This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI ≥ 8 or ≤ 12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS f…

Cancer ResearchCarcinoma Ovarian EpithelialRandomised clinical trialCarboplatinCytoreductionchemistry.chemical_compoundPostoperative Complications0302 clinical medicineQuality of lifeAntineoplastic Combined Chemotherapy ProtocolsNeoplasms Glandular and EpithelialOvarian Neoplasms030219 obstetrics & reproductive medicineCytoreduction Surgical ProceduresMiddle AgedDebulkingOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemalemedicine.symptomAdultQuality of lifemedicine.medical_specialtyAdolescentPaclitaxelNauseaOperative TimeYoung Adult03 medical and health sciencesOvarian cancerBody ImagemedicineHumansProgression-free survivalAgedAnalysis of VarianceAdvanced ovarian cancer; Cytoreduction; Laparoscopy; Peri-operative complications; Quality of life; Randomised clinical trialbusiness.industryPeri-operative complicationsPerioperativeLength of StayCarboplatinSurgeryClinical trialSettore MED/40 - GINECOLOGIA E OSTETRICIAchemistryAdvanced ovarian cancerLaparoscopyPeri-operative complicationComplicationbusiness
researchProduct

Thyroid Cancer Resistance to Chemotherapeutic Drugs via Autocrine Production of Interleukin-4 and Interleukin-10

2003

We investigated the mechanisms responsible for the widespread refractoriness to chemotherapeutic drugs observed in thyroid cancers. We show that malignant epithelial cells from papillary, follicular, and anaplastic thyroid carcinomas express high levels of Bcl-2 and Bcl-xL. Exogenous expression of either Bcl-2 or Bcl-xL in normal thyrocytes was sufficient to prevent chemotherapeutic drug-induced cytotoxicity. All of the histological thyroid cancer variants examined produced interleukin-4 (IL-4) and interleukin-10 (IL-10), which increased Bcl-2 and Bcl-xL levels and protected thyroid cells from chemotherapeutic agents. Exposure to neutralizing antibodies against IL-4 and IL-10 resulted in do…

Cancer ResearchCell DeathPaclitaxelCancer Research; OncologyCarcinomaThyroid Glandbcl-X ProteinAntineoplastic AgentsApoptosisThyroid Cancer Interleukin-4 Interleukin-10Middle AgedCarcinoma PapillaryInterleukin-10OncologyProto-Oncogene Proteins c-bcl-2Settore MED/04 - PATOLOGIA GENERALEDoxorubicinDrug Resistance NeoplasmHumansInterleukin-4Thyroid NeoplasmsCisplatinAged
researchProduct

Tumor Hypoxia: Causative Factors, Compensatory Mechanisms, and Cellular Response

2004

Abstract Learning Objectives After completing this course, the reader will be able to: Explain the effect of hypoxia on resistance to treatment. Describe the causes of tumor hypoxia. Characterize cellular response to hypoxia. Access and take the CME test online and receive 1 hour of AMA PRA category 1 credit at CME.TheOncologist.com Hypoxia is a characteristic feature of locally advanced solid tumors resulting from an imbalance between oxygen (O2) supply and consumption. Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O2 tra…

Cancer ResearchCell SurvivalAnemiamedicine.medical_treatmentPhotodynamic therapyDiseaseNeoplasmsmedicineHumansNeovascularization PathologicTumor hypoxiabusiness.industryAnemiaTumor OxygenationHypoxia (medical)medicine.diseaseAdaptation PhysiologicalCell HypoxiaOxygenRadiation therapyCell Transformation NeoplasticOncologyDrug Resistance NeoplasmImmunologyDisease ProgressionCancer researchHemoglobinmedicine.symptombusinessThe Oncologist
researchProduct